Peptide Profiles

A synthetic 15-amino-acid peptide studied primarily in animal models for tissue healing, gut repair, and anti-inflammatory effects. Evidence is limited to preclinical research.

A synthetic 29-amino-acid GHRH receptor agonist with four stability substitutions and a ~30-minute half-life, structurally identical to the core of CJC-1295 WITH-DAC but without albumin binding. Evidence is limited to animal and in vitro studies; no published efficacy trial tests this compound alone.

CJC-1295 DAC is a 30-amino-acid synthetic GHRH analog engineered to covalently bind serum albumin, extending its half-life from minutes to roughly one week and sustaining GH / IGF-1 elevation for days after a single dose in preclinical and limited early-phase research.

Epitalon is a synthetic four-amino-acid peptide (AEDG), developed by a single research group in St. Petersburg as the putative active fraction of a bovine pineal extract, with in vitro telomerase-upregulation data and animal lifespan studies, but evidence is limited to animal and in vitro research.

A synthetic five-amino-acid pentapeptide that selectively agonizes the ghrelin receptor (GHS-R1a) to trigger pulsatile growth hormone release, with evidence limited to animal and in vitro studies plus one failed preclinical-to-clinical translation attempt.

KPV is a three-amino-acid C-terminal fragment of α-MSH with documented anti-inflammatory activity in mouse colitis and rabbit corneal-wound models, with evidence limited to animal and in vitro studies.

Melanotan II is a synthetic, non-selective melanocortin agonist sold online as a "tanning injection," with a harm record far better documented than its benefits, which are supported only by animal and limited preclinical research.

MOTS-c is a 16-amino-acid mitochondrially-encoded peptide with observational evidence tying low circulating levels to metabolic disease, but an interventional evidence base limited entirely to animal and in vitro studies for the native peptide.

A synthetic three-amino-acid peptide (Glu-Asp-Arg) developed by the Khavinson group in St. Petersburg and studied almost entirely in cell and animal models as a possible brain-protecting molecule, with no independent replication outside that research network.

A name that refers to either a synthetic 7-amino-acid peptide (Ac-LKKTETQ, the original veterinary product) or the full-length 43-residue thymosin beta-4; research peptide vendors typically sell the latter under the "TB-500" label despite the two being structurally distinct.